

IMMUNOME, INC.

**CHARTER OF THE SCIENCE AND TECHNOLOGY COMMITTEE
OF THE BOARD OF DIRECTORS**

APPROVED BY THE BOARD OF DIRECTORS

JULY 12, 2021

PURPOSE AND POLICY

The primary purpose of the Science and Technology Committee (the “*Committee*”) of the Board of Directors (the “*Board*”) of Immunome, Inc. (together with its consolidated subsidiaries, the “*Company*”) shall be to oversee the Company’s research and development activities on behalf of the Board.

COMPOSITION

The Committee shall consist of at least two (2) members of the Board. Each member of the Committee shall satisfy (i) the independence requirements imposed by any stock exchange on which any of the Company’s capital stock is listed, including any exceptions permitted by such requirements, as determined by the Board and (ii) any other qualifications determined by the Board. The members of the Committee shall be appointed by and serve at the discretion of the Board. Vacancies occurring on the Committee shall be filled by the Board. The Committee’s chairperson shall be appointed by the Board.

MEETINGS AND MINUTES

The Committee shall hold such regular or special meetings as its members shall deem necessary or appropriate. Minutes of each meeting of the Committee shall be prepared and distributed to each director of the Company and the Secretary of the Company after each meeting. The Chairperson of the Committee shall report to the Board from time to time or whenever so requested by the Board.

A majority of the members shall represent a quorum of the Committee, and, if a quorum is present, any action approved by a majority of the members present shall represent the valid action of the Committee. Any actions taken by the Committee during any period in which one or more members fail for any reason to meet the membership requirements set forth above shall be nonetheless duly authorized actions of the Committee for all corporate purposes. The Committee may act by unanimous written consent; when it does so, those actions will be filed in the minute book.

AUTHORITY

The Committee shall have access to all books, records, facilities and personnel of the Company as deemed necessary or appropriate by any member of the Committee to discharge their

responsibilities hereunder. The Committee shall have access to and shall communicate with the Board, committee chairpersons, members of senior management and independent professional advisors to the Board and its various committees, as applicable. The Committee shall have the authority to obtain, at the expense of the Company, advice and assistance from internal or external legal, accounting or other advisors and consultants. The Committee shall have the authority to approve fees, costs and other terms of engagement of such outside resources. The Committee shall also have authority to pay, at the expense of the Company, ordinary administrative expenses (including expenditures for external resources) that, as determined by the Committee, are necessary or appropriate in carrying out its duties. The Committee shall have authority to require that any of the Company's personnel, counsel, accountants or investment bankers, or any other consultant or advisor to the Company, attend any meeting of the Committee or meet with any member of the Committee or any of its special, outside legal, accounting or other, advisors or consultants.

The Committee may form and delegate authority to one or more subcommittees as appropriate, consisting of one or more members of the Board (whether or not they are on the Committee) to the extent allowed under applicable law and stock exchange listing requirements. Delegation by the Committee to any subcommittee shall not limit or restrict the Committee on any matter so delegated, and, unless the Committee alters or terminates such delegation, any action by the Committee on any matter so delegated shall not limit or restrict future action by such subcommittee on such matters. The operation of the Committee shall be subject to the Bylaws of the Company as in effect from time to time and Section 141 of the Delaware General Corporation Law. The approval of this Charter shall be construed as a delegation of authority to the Committee with respect to the responsibilities set forth herein.

RESPONSIBILITIES

To implement the Committee's purpose, the Committee shall have the following responsibilities. The Committee may supplement and, except as otherwise required by applicable law or the requirements of any stock exchange on which any of the Company's capital stock is then listed, deviate from these activities as appropriate under the circumstances:

1. *Research and Development Programs.* Review, evaluate and advise the Board and management regarding goals and objectives for the Company's research and development programs, the Company's pipeline and the quality and direction of the Company's platform, programs and products. Review, evaluate and advise the Board regarding the Company's progress in achieving its research and development-related goals and objectives. Monitor the Company's progress regarding the advancement of the Company's programs.

2. *Regulatory Pathway.* Monitor and consult with management regarding the clinical development, pharmacovigilance, medical affairs and regulatory affairs functions of the Company and advise on strategies regarding the same. Evaluate trends in regulatory regimes and relation to the Company's proposed regulatory path for its programs and products.

3. *Strategic Matters.* Review and recommend approaches to acquiring, divesting and maintaining technology positions (including licenses, collaborations and alliances) and making investments in the same. Assess the scientific aspects of business development transactions.

4. **Market Trends.** Identify and discuss significant emerging trends and issues in science and technology and the competitive landscape, and recommend to the Board and management emerging technologies for the Company to pursue. Review, evaluate and advise the Board regarding the quality, direction and competitiveness of the Company's research and development programs.

5. **Intellectual Property Portfolio.** Consult with management regarding the Company's intellectual property portfolio and the prosecution, maintenance and protection of the same in support of the Company's new product development and lifecycle management efforts.

6. **Committee Self-Assessment; Charter.** The Committee shall review, discuss and assess its own performance at least annually. The Committee shall also periodically assess the adequacy of this charter and shall recommend any proposed changes to the Board for its consideration.

7. **General Authority.** The Committee shall perform such other functions and have such other powers as may be necessary or appropriate in the discharge of the foregoing and such other powers as are delegated by the Board.